319 - Lineage and William Demant Invest Partner to Advance Cell Therapy for Hearing Loss
Description
Can lost hearing cells be replaced? Lineage Cell Therapeutics CEO Brian Culley returns to discuss the company’s new collaboration with William Demant Invest. Together, they’re advancing ReSonance™ (ANP1) — an experimental cell therapy designed to replace damaged auditory neurons and potentially restore communication between the ear and the brain.Culley explains how the partnership combines Lineage’s regenerative cell technology with the audiology expertise of Eriksholm Research Centre to move this therapy toward first-in-human testing. Backed by up to $12 million in research funding, the multi-year effort could represent a new frontier in treating hearing loss in the future.Be sure to subscribe to our channel for the latest episodes each week and follow This Week in Hearing on LinkedIn, Instagram and X.
- - https://x.com/WeekinHearing
- - https://www.instagram.com/thisweekinhearing/
- - https://www.linkedin.com/company/this-week-in-hearing
Visit us at: https://hearinghealthmatters.org/thisweek/
United States
